BMG Pharma is pleased to announce positive clinical results on gelx® the first breakthrough product to achieve prevention of oral mucositis in cancer patients.

November 16 2017 Milan, Italy: BMG Pharma S.r.l., an innovative specialty pharmaceutical company, is pleased to announce the first efficacy data on its GelX® product for the prevention of oral mucositis. The new clinical data, (conducted under Good Clinical Practice(GCP) principles) from 149 adult and paediatric patients has shown unique results for the first time, […]

Read More
Presentation of new GelX® data at the forthcoming CPHi Worldwide Congress, 25th October 2017.

July 10th 2017 Milan, Italy: BMG Pharma S.r.l., an innovative specialty pharmaceutical company, announces it will be presenting significant newly generated efficacy data on its GelX® product for the treatment of oral mucositis at the forthcoming CPHi Worldwide event in Frankfurt, October 2017. Marco Mastrodonato, CEO of BMG Pharma S.r.l. commented– “This new data is a […]

Read More
Milan, Italy: Pierre Fabre Pharmaceuticals and BMG Pharma S.r.l announce the signature of a Distribution and Supply Agreement for AFTACURE Gel and AFTACURE Spray in different territories

May 15th 2017: * Pierre Fabre Oral Care, a brand of Pierre Fabre Pharmaceuticals, is one of the leaders in Europe in oral and dental hygiene products with its ranges of products presented to dentists across Europe  * Thanks to this agreement in line with its open innovation strategy, Pierre Fabre Oral Care expands  and […]

Read More
Milan, Italy: BMG PHARMA S.r.l announces the achievement of the Certificate for ISO 13485.

January 18th 2016 BMG Pharma S.r.l. is pleased to announce the achievement of the ISO Certificate 13485 from TÜV Süd. The Certificate issued by TÜV Süd America Inc., USA, certifies that BMG has established and is maintaining a quality management system that meets the requirements of ISO 13485:2003 and is in compliance with the Health Canada […]

Read More
Milan, Italy: BMG PHARMA S.r.l announces the issue of results of clinical studies related to its proprietary products GelX oral Gel and GelX Oral Spray.

November 9th 2015 BMG Pharma S.r.l. is pleased to announce the publication of results of clinical studies related to GelX® Oral Gel and GelX® Oral Spray. GelX® Oral Gel and GelX ® Oral Spray are proprietary products of BMG Pharma Srl, Thanks to its innovative formulas, the GelX® range alleviates pain in oncological patients, offering […]

Read More
BMG PHARMA S.r.l announces the signature of a Distribution Agreement for its Cancer Supportive Care line including its iron in liposomal technology based product with Sayre Therapeutics for India and other Asian area countries.

July 30th 2015 BMG Pharma S.r.l. is pleased to announce the signature of a Distribution Agreement with Sayre Therapeutics Ltd, Bangalore, India, for its cancer supportive products under the brand name GelX® and for its liposomal iron based food supplement   IronOne. Thanks to its innovative formulas, the GelX® range alleviates pain in oncological patients, […]

Read More